Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Psoas Muscles | 1 | 2021 | 28 | 0.94 | Why? |
| Hematoma | 1 | 2021 | 305 | 0.71 | Why? |
| Heparin, Low-Molecular-Weight | 3 | 2021 | 1731 | 0.69 | Why? |
| Thrombophilia | 2 | 2021 | 1935 | 0.47 | Why? |
| HIV Reverse Transcriptase | 3 | 2019 | 104 | 0.40 | Why? |
| HIV-1 | 5 | 2019 | 3365 | 0.31 | Why? |
| Intubation, Intratracheal | 1 | 2021 | 3962 | 0.29 | Why? |
| Anticoagulants | 2 | 2021 | 9563 | 0.25 | Why? |
| HIV Infections | 8 | 2021 | 11620 | 0.23 | Why? |
| Drug Resistance, Viral | 2 | 2019 | 1083 | 0.22 | Why? |
| Reverse Transcriptase Inhibitors | 2 | 2020 | 309 | 0.21 | Why? |
| HIV Protease | 2 | 2017 | 86 | 0.21 | Why? |
| P-Selectin | 1 | 2021 | 224 | 0.20 | Why? |
| Rome | 1 | 2021 | 497 | 0.20 | Why? |
| Pyridones | 2 | 2020 | 738 | 0.16 | Why? |
| Fluorenes | 1 | 2017 | 101 | 0.16 | Why? |
| Muscular Diseases | 1 | 2021 | 392 | 0.15 | Why? |
| Molecular Typing | 1 | 2017 | 280 | 0.15 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.15 | Why? |
| Hepatitis C | 2 | 2017 | 1514 | 0.15 | Why? |
| Central Nervous System | 1 | 2020 | 701 | 0.14 | Why? |
| Triazoles | 1 | 2019 | 440 | 0.14 | Why? |
| Benzimidazoles | 1 | 2017 | 275 | 0.13 | Why? |
| Hospital Mortality | 4 | 2021 | 22087 | 0.13 | Why? |
| Biological Evolution | 1 | 2018 | 641 | 0.12 | Why? |
| Sofosbuvir | 1 | 2017 | 518 | 0.12 | Why? |
| Anti-Retroviral Agents | 1 | 2020 | 1099 | 0.11 | Why? |
| Kaplan-Meier Estimate | 1 | 2021 | 4260 | 0.11 | Why? |
| Anti-HIV Agents | 2 | 2019 | 2209 | 0.09 | Why? |
| Antimalarials | 1 | 2021 | 2505 | 0.09 | Why? |
| Hepatitis B | 1 | 2017 | 888 | 0.09 | Why? |
| Respiratory System | 1 | 2021 | 3213 | 0.09 | Why? |
| Heparin | 1 | 2021 | 2600 | 0.09 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.09 | Why? |
| Blood Coagulation Disorders | 1 | 2021 | 2040 | 0.09 | Why? |
| DNA, Viral | 1 | 2017 | 2521 | 0.08 | Why? |
| Italy | 5 | 2021 | 38444 | 0.08 | Why? |
| Gastrointestinal Diseases | 1 | 2021 | 2580 | 0.08 | Why? |
| Glucocorticoids | 1 | 2021 | 4431 | 0.07 | Why? |
| Coinfection | 3 | 2020 | 6820 | 0.07 | Why? |
| Magnetic Resonance Imaging | 1 | 2021 | 6551 | 0.07 | Why? |
| Middle Aged | 13 | 2021 | 270681 | 0.07 | Why? |
| Virus Shedding | 1 | 2021 | 5834 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| Male | 13 | 2021 | 367725 | 0.06 | Why? |
| Female | 13 | 2021 | 380317 | 0.06 | Why? |
| Aged | 7 | 2021 | 215776 | 0.05 | Why? |
| Treatment Outcome | 3 | 2021 | 51732 | 0.05 | Why? |
| Delavirdine | 1 | 2019 | 5 | 0.05 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.05 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.05 | Why? |
| Alkynes | 1 | 2019 | 98 | 0.05 | Why? |
| Nevirapine | 1 | 2019 | 57 | 0.05 | Why? |
| Rilpivirine | 1 | 2019 | 65 | 0.05 | Why? |
| Oxazines | 1 | 2020 | 279 | 0.05 | Why? |
| HIV Integrase Inhibitors | 1 | 2020 | 173 | 0.05 | Why? |
| Benzoxazines | 1 | 2019 | 103 | 0.05 | Why? |
| Sequence Analysis, RNA | 2 | 2018 | 2290 | 0.05 | Why? |
| Pyridazines | 1 | 2019 | 86 | 0.05 | Why? |
| HIV Long Terminal Repeat | 1 | 2017 | 16 | 0.05 | Why? |
| Critical Illness | 1 | 2021 | 17281 | 0.04 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2020 | 275 | 0.04 | Why? |
| Humans | 18 | 2021 | 930598 | 0.04 | Why? |
| Adaptation, Biological | 1 | 2018 | 179 | 0.04 | Why? |
| Piperazines | 1 | 2020 | 445 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.04 | Why? |
| Retrospective Studies | 4 | 2021 | 105322 | 0.04 | Why? |
| Henipavirus Infections | 1 | 2018 | 122 | 0.04 | Why? |
| Tenofovir | 1 | 2020 | 449 | 0.04 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.04 | Why? |
| Survival Analysis | 2 | 2021 | 7592 | 0.04 | Why? |
| Th2 Cells | 1 | 2020 | 680 | 0.04 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.04 | Why? |
| Cyclopropanes | 1 | 2019 | 332 | 0.04 | Why? |
| Transgender Persons | 1 | 2020 | 322 | 0.04 | Why? |
| RNA, Viral | 2 | 2021 | 32276 | 0.04 | Why? |
| Hepatitis B Antibodies | 1 | 2017 | 142 | 0.04 | Why? |
| CD4 Lymphocyte Count | 1 | 2020 | 1517 | 0.04 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.04 | Why? |
| Purines | 1 | 2021 | 816 | 0.04 | Why? |
| Hepatitis B Surface Antigens | 1 | 2017 | 305 | 0.04 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.04 | Why? |
| Tomography, X-Ray Computed | 1 | 2021 | 25144 | 0.04 | Why? |
| Azetidines | 1 | 2021 | 722 | 0.04 | Why? |
| Phylogeny | 3 | 2017 | 13341 | 0.03 | Why? |
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 552 | 0.03 | Why? |
| Th1 Cells | 1 | 2020 | 1228 | 0.03 | Why? |
| Automation, Laboratory | 1 | 2017 | 536 | 0.03 | Why? |
| Cytokines | 3 | 2021 | 15010 | 0.03 | Why? |
| Leukocytes | 1 | 2021 | 1046 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2020 | 1262 | 0.03 | Why? |
| Nitriles | 1 | 2019 | 1053 | 0.03 | Why? |
| Cluster Analysis | 1 | 2021 | 3001 | 0.03 | Why? |
| Sulfonamides | 1 | 2021 | 1294 | 0.03 | Why? |
| Databases, Genetic | 1 | 2017 | 1127 | 0.03 | Why? |
| Pyrimidines | 1 | 2019 | 1557 | 0.03 | Why? |
| Endothelial Cells | 1 | 2021 | 2048 | 0.03 | Why? |
| Interferon-gamma | 1 | 2020 | 2711 | 0.03 | Why? |
| Pyrazoles | 1 | 2021 | 1791 | 0.03 | Why? |
| Blood Platelets | 1 | 2021 | 1704 | 0.03 | Why? |
| Adult | 7 | 2021 | 244371 | 0.02 | Why? |
| Hepatitis B virus | 1 | 2017 | 882 | 0.02 | Why? |
| Base Sequence | 1 | 2017 | 3581 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2021 | 6543 | 0.02 | Why? |
| Immune Evasion | 1 | 2018 | 2081 | 0.02 | Why? |
| Risk | 1 | 2020 | 5288 | 0.02 | Why? |
| Bayes Theorem | 1 | 2017 | 3237 | 0.02 | Why? |
| Blood Coagulation | 1 | 2021 | 2768 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2020 | 4849 | 0.02 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.02 | Why? |
| Molecular Dynamics Simulation | 1 | 2017 | 4155 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Antigens, Viral | 1 | 2020 | 6298 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Time Factors | 1 | 2021 | 31397 | 0.01 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2020 | 25288 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2019 | 53120 | 0.01 | Why? |
| Risk Factors | 1 | 2020 | 71621 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.01 | Why? |
| Adolescent | 1 | 2020 | 86841 | 0.01 | Why? |
| Young Adult | 1 | 2020 | 93724 | 0.01 | Why? |
| Antibodies, Viral | 1 | 2020 | 51949 | 0.01 | Why? |
| Antiviral Agents | 1 | 2017 | 41703 | 0.00 | Why? |
| Pandemics | 2 | 2021 | 389249 | 0.00 | Why? |